OncoZenge develops better products for the supportive care of cancer patients.
OncoZenge has raised $3.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
OncoZenge's investors include Sichuan Yangtian Bio-Pharmaceutical, Ostersjöstiftelsen, Linc, John Haurum.
OncoZenge is headquartered in Bromma, Sweden.
OncoZenge develops better products for the supportive care of cancer patients.
OncoZenge is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoZenge — Funding & Investors." VCBacked, September 22, 2026, https://www.vcbacked.co/company/oncozenge. Accessed October 3, 2026.
VCBacked. (2026). OncoZenge — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/oncozenge
{{cite web |title=OncoZenge — Funding & Investors |url=https://www.vcbacked.co/company/oncozenge |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated